BioSpace News Archive

Kamada Ltd. today announced that Kedrion has exercised its option to extend the distribution agreement between the parties in the U.S. for KEDRAB® (Rabies Immune Globulin [Human]), which is indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection to persons of all ages when given immediately after contact with a rabid or possibly rabid animal.

Conference call to be held on Thursday, July 27, 2023, at 8:30 a.m. Eastern Time.

Evelo Biosciences, Inc. today announces that it closed the previously announced private placement, resulting in gross proceeds of approximately $25.5 million from the sale of 11,025,334 shares of its common stock at a purchase price of $2.31 per share.

Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation.

Liminal BioSciences Inc. today announced that they have entered into a definitive arrangement agreement (the “Arrangement Agreement”) under which SALP will acquire all of the issued and outstanding common shares of Liminal BioSciences (the “Common Shares”) that it does not already own.

Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARK CT.

iCAD, Inc today announced its “ProFound Insights, ProFound Impact” webinar series will feature Dr. Laura Dean, a renowned breast radiologist at the Cleveland Clinic. Titled “How Cleveland Clinic is Finding the Breast Cancers Radiologists Fear the Most,” the live event will take place on Thursday, July 20 at 10 am ET.

INmune Bio, Inc. has been invited to discuss drug development strategies in aging and rejuvenation at the 5th World Aging and Rejuvenation Conference in Frankfurt, Germany on July 17, 2023.

Daxor Corporation announces a new research letter in the Journal of the American College of Cardiology – Heart Failure validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients.

Apnimed, Inc. announced today that it will be participating in a fireside chat at the William Blair Conference, Transitioning Biotech Breakthroughs to Commercial Success, taking place virtually on Tuesday, July 18, 2023 at 8 a.m. ET.